Download - High-Risk/End-stage Patient With Functional MR: Should We Treat with Anything? Steven R. DeBeer, MD Cardiothoracic Surgery Fellow Emory University AATS.

Controlled Intermittent Asystole: Pharmacologic Potentiation of Vagal-Induced Asystole

DisclosuresNone

Preoperative AssessmentPulmonary Function TesteingFVC:Post BD=1.23 (50%)FEV1:Post BD=0.78 (42%)DLCO:8.4 (45%)Current Medical ManagementBeta-blockerASAStatinARBAldosterone antagonistLoop diureticInhaled steroid/beta-agonistInsulin

TEE

EF=20%Severe global hypokinesisAkinetic apexMod-severe MRCentral secondary to restricted P2 scallop mobilityCoaptation length